Emergent closes on buying smallpox drug Tembexa from Chimerix with a $238M payment

It was only last year that the oral treatment Tembexa was approved by the FDA to treat smallpox, but the drug has already changed hands.

Emergent BioSolutions, one of the primary drug manufacturers for the US government, has grabbed the global rights for Tembexa from the North Carolina-based biotech Chimerix….
Click here to view original post